Emerging Markets Earnings Roundup: Amgen, Bristol Myers Squibb (Part 1)
This article was originally published in PharmAsia News
After tackling Brazil and Turkey, Amgen looks to ramp up in Japan and China, while BMS talks up its first-to-market opportunity for an all-oral hepatitis C regimen in Japan.
You may also be interested in...
Bristol remains plagued by the loss of exclusivity for Plavix and setbacks in 2012, but the company hopes to paint a picture of growth as newly approved drugs begin to fill the revenue gap.
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.